(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 November 2014 (20.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/186403 A2

(51) **International Patent Classification**:
A61K 47/48 (2006.01) *C07K 16/28* (2006.01)
A61K 31/573 (2006.01) *A61K 39/395* (2006.01)

(21) **International Application Number**:
PCT/US2014/037911

(22) **International Filing Date**:
13 May 2014 (13.05.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/823,317 14 May 2013 (14.05.2013) US
61/828,586 29 May 2013 (29.05.2013) US

(71) **Applicant**: **IMMUNOGEN INC.** [US/US]; 830 Winter Street, Waltham, Massachusetts 02451 (US).

(72) **Inventors**: **RUNNING, Kelli**; 9 Falls Circle, Colchester, Connecticut 06415 (US). **MASTICO, Robert A.**; 29 Woodman Terrace, Hanson, Massachusetts 02341 (US). **O'LEARY, James J.**; 273 Watertown Street, Newton, Massachusetts 02458 (US). **AB, Olga**; 26 Bayberry Circle, Millis, Massachusetts 02054 (US). **WOLF, Beni B.**; 29 Fairbanks Road, Lexington, Massachusetts 02421 (US).

(74) **Agents**: **STEFFE, Eric K.** et al.; Sterne, Kessler, Goldstein & Fox PLLC, 1100 New York Avenue, N.W., Washington, District of Columbia 20005-3934 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2014/186403 A2

(54) **Title**: ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS

(57) **Abstract**: Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.